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Monoclonal antibody inhibitors against cathepsin-K, Rank-ligand or sclerostin are the therapeutic tools of tomorrow for osteoporosis. Once-a-year infusion, for 3 years, of 5 mg zoledronate reduces the risk of vertebral and hip fractures. 5 mg-infusion of zoledronate in the 90 days following hip fracture, then annual, decreases new clinical fractures and improves survival. 150 mg-risedronate monthly has the same effects than 5 mg daily. Report of osteonecrosis of the jaw associated with bisphosphonate therapy in osteoporosis is low, less than 1/100,000. As raloxifene, basedoxifene reduces the rate of vertebral fractures. Despite its anti-fracture efficacy and safety, strontium ranelate is not available in Switzerland. We need strategies to improve patient's adherence to treatment in osteoporosis.